3 Generic Drug Stocks to Watch Amid Improving Industry Trends

The generic drug industry is experiencing a mixed but resilient operating environment with pricing pressures offset by healthy underlying demand and new product launches. Three companies—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through biosimilar expansion, complex generics development, and operational efficiency improvements. The industry currently trades at a valuation discount compared to broader market indices.